Gary Phillips

About Gary Phillips

Dr. Gary M. Phillips is an internationally experienced life sciences executive and currently serves as Chairman of the Supervisory Board of Nanobiotix, a role he has held since May 2021. At Nanobiotix, the French, publicly listed biopharmaceutical company focused on physics-based approaches to cancer treatment, he contributes senior oversight and strategic guidance during a critical phase of clinical development and global expansion. His board leadership is closely aligned with governance, long-term growth, and the company’s efforts to advance and monetize its core technology platform. Before joining Nanobiotix, Phillips was President and Chief Executive Officer of OrphoMed, Inc. He previously served as Executive Vice President and Chief Strategy Officer at Mallinckrodt Pharmaceuticals, where he was involved in corporate strategy and development priorities. His career also includes senior leadership positions at Bausch & Lomb, where he held dual roles as President of U.S. Surgical and Pharmaceuticals and Global Head of Pharmaceuticals. In addition, he has held executive responsibilities at Reckitt Benckiser Pharmaceuticals North America, Merck Serono, Novartis, and Wyeth. Phillips also brought a broader global perspective through his work at the World Economic Forum, where he served as Head of Global Health & Healthcare Industries. That experience added depth in public health, healthcare innovation, stakeholder engagement, and the structural challenges of improving access to care. Across these roles, he has built a reputation for combining operational discipline with strategic thinking in complex, highly regulated environments. His background is also strongly rooted in medicine and academic excellence. He earned a B.A. in biochemistry from the University of Pennsylvania, an MBA from the Wharton School, and an M.D. from the Perelman School of Medicine, graduating with Alpha Omega Alpha distinction. He also served as a general medicine clinician/officer in the U.S. Navy. This blend of medical training, corporate leadership, and international healthcare experience makes him particularly well suited to oversee a company such as Nanobiotix, where clinical credibility, regulatory execution, and commercial strategy are all essential to long-term success.